Conor Gallagher, Ph.D.
Conor Gallagher, Ph.D. is Chief Scientific Officer at Revance. His relevance to the botulinum toxin industry comes from current scientific leadership at Revance / Crown Laboratories and Daxxify.
His role complements Thomas Hitchcock, Ph.D., who anchors Revance’s innovation-leadership context. Gallagher is most relevant to Revance’s product-development and medical-science framing after Crown’s acquisition.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Revance |
| Current role | Chief Scientific Officer |
| Company context | Revance within the Crown Laboratories corporate group |
| Relevant company | Revance / Crown Laboratories |
| Relevant brand | Daxxify |
| Official leadership source | Revance: Leadership Team and Board of Directors 🔗 |
Career Notes
Section titled “Career Notes”- Revance identifies Gallagher as Chief Scientific Officer on its current leadership page.
- Revance’s science materials describe work across innovation, medical affairs, clinical studies, and sponsored-trial support.
- Revance describes Daxxify as a peptide-formulated neuromodulator developed and manufactured by Revance.
- Daxxify’s U.S. prescribing information remains the source for product-specific indications, warnings, dosing language, and unit cautions.
Scientific Leadership Context
Section titled “Scientific Leadership Context”Gallagher’s role separates current science leadership from broader promotional discussion around Daxxify. Revance’s product-science framing matters because Daxxify is often discussed through formulation, duration, and innovation language.
That language needs a narrow interpretation. A scientific-leadership connection does not establish that Daxxify is safer, stronger, longer-lasting, or clinically superior to other botulinum toxin products. Product comparisons require product-specific labels, evidence, and market context.
Activity and Public Context
Section titled “Activity and Public Context”Revance’s current public materials position the company across aesthetics, skincare, and therapeutics. For toxin-market interpretation, Gallagher’s most relevant connection is Daxxify and the current Revance science organization supporting product development, medical affairs, and clinical context.
Gallagher pairs naturally with other science and R&D leaders, including Darin J. Messina, Ph.D. at AbbVie / Allergan Aesthetics and Thomas Hitchcock, Ph.D. at Revance.